Genetic lesions that are typically detectable in CMML include mutations in SRSF2 (about 50% of patients), TET2 (50–60%), and ASXL1 (35–49%) (Table 1). This evidence concerns the gene ASXL1 and chronic myelomonocytic leukemia.